$SKYE
Skye Bioscience, Inc.

2023 Q4 Form 10-Q Financial Statement

#000151655123000100 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.495M $2.240M
YoY Change 61.95% 96.39%
% of Gross Profit
Research & Development $1.591M $1.255M
YoY Change 3.53% -29.58%
% of Gross Profit
Depreciation & Amortization $24.25K $30.00K
YoY Change -23.09% 4.13%
% of Gross Profit
Operating Expenses $4.086M $24.71M
YoY Change 32.77% 745.43%
Operating Profit -$24.71M
YoY Change 745.43%
Interest Expense -$379.8K $271.3K
YoY Change 152.45% 28.44%
% of Operating Profit
Other Income/Expense, Net $0.00 -$240.1K
YoY Change -100.0% 17.11%
Pretax Income -$4.420M -$24.95M
YoY Change -55.31% 697.68%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.420M -$24.95M
YoY Change -55.32% 697.68%
Net Earnings / Revenue
Basic Earnings Per Share -$3.17
Diluted Earnings Per Share -$0.36 -$3.17
COMMON SHARES
Basic Shares Outstanding 12.34M shares 971.5M shares
Diluted Shares Outstanding 7.881M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.429M $5.130M
YoY Change 14.81% 1134.98%
Cash & Equivalents $10.34M $5.126M
Short-Term Investments
Other Short-Term Assets $888.9K $867.9K
YoY Change 115.75% 503.31%
Inventory
Prepaid Expenses $425.3K $207.2K
Receivables
Other Receivables
Total Short-Term Assets $11.65M $15.29M
YoY Change 30.27% 469.68%
LONG-TERM ASSETS
Property, Plant & Equipment $43.28K $55.28K
YoY Change -50.74% -35.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.309K $8.309K
YoY Change 0.0% 0.0%
Total Long-Term Assets $289.6K $318.1K
YoY Change 73.03% 71.47%
TOTAL ASSETS
Total Short-Term Assets $11.65M $15.29M
Total Long-Term Assets $289.6K $318.1K
Total Assets $11.94M $15.60M
YoY Change 31.05% 443.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.156M $1.631M
YoY Change -30.79% -21.1%
Accrued Expenses $2.069M $1.280M
YoY Change 175.09% 52.01%
Deferred Revenue
YoY Change
Short-Term Debt $4.372M $4.170M
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $13.90M $13.72M
YoY Change 14.7% 123.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $171.2K $190.0K
YoY Change 2208.63%
Total Long-Term Liabilities $171.2K $190.0K
YoY Change 2208.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.90M $13.72M
Total Long-Term Liabilities $171.2K $190.0K
Total Liabilities $14.07M $13.91M
YoY Change 16.12% 126.02%
SHAREHOLDERS EQUITY
Retained Earnings -$104.4M -$99.96M
YoY Change 56.41% 75.85%
Common Stock $102.3M $101.7M
YoY Change 60.44% 89.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.132M $1.695M
YoY Change
Total Liabilities & Shareholders Equity $11.94M $15.60M
YoY Change 31.05% 443.93%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$4.420M -$24.95M
YoY Change -55.32% 697.68%
Depreciation, Depletion And Amortization $24.25K $30.00K
YoY Change -23.09% 4.13%
Cash From Operating Activities -$3.842M -$4.060M
YoY Change -21.13% 97.41%
INVESTING ACTIVITIES
Capital Expenditures $2.550K $10.00K
YoY Change -100.71% -102.73%
Acquisitions
YoY Change
Other Investing Activities -$990.00 $1.080M
YoY Change -100.02%
Cash From Investing Activities -$3.540K $1.070M
YoY Change -100.06% -392.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -26.73K 16.64M
YoY Change -178.23% -18216.49%
NET CHANGE
Cash From Operating Activities -3.842M -4.060M
Cash From Investing Activities -3.540K 1.070M
Cash From Financing Activities -26.73K 16.64M
Net Change In Cash -3.872M 13.65M
YoY Change -567.03% -642.85%
FREE CASH FLOW
Cash From Operating Activities -$3.842M -$4.060M
Capital Expenditures $2.550K $10.00K
Free Cash Flow -$3.845M -$4.070M
YoY Change -14.83% 140.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Operating Income Loss
OperatingIncomeLoss
-9028662 usd
CY2022Q3 skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-6228 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
271307 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
211229 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
24705766 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2922282 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-30648916 usd
CY2023Q3 skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
0 usd
skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-3 usd
skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-59406 usd
us-gaap Interest Expense
InterestExpense
476135 usd
us-gaap Interest Expense
InterestExpense
615563 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
16562 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
49669 usd
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
CY2022Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
1383285 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
CY2023Q3 skye Wind Down Costs
WindDownCosts
-14677 usd
CY2022Q3 skye Wind Down Costs
WindDownCosts
0 usd
skye Wind Down Costs
WindDownCosts
455504 usd
skye Wind Down Costs
WindDownCosts
0 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-240068 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-205001 usd
us-gaap Net Income Loss
NetIncomeLoss
-9589960 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.83
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.83
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7880546 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1983700 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5207411 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1983566 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7880546 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1983700 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5207411 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1983566 shares
us-gaap Net Income Loss
NetIncomeLoss
-33224854 usd
us-gaap Net Income Loss
NetIncomeLoss
-9589960 usd
us-gaap Depreciation
Depreciation
95880 usd
us-gaap Depreciation
Depreciation
83466 usd
us-gaap Share Based Compensation
ShareBasedCompensation
394657 usd
us-gaap Share Based Compensation
ShareBasedCompensation
425846 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-59406 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
102400 usd
skye Accrued Interest Conversion Expense
AccruedInterestConversionExpense
0 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001516551
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.004
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12338910 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5126245 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
9084799 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
207226 usd
CY2023Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
6432216 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
481588 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
8943718 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87854 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
71191 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8309 usd
CY2022Q4 us-gaap Assets
Assets
9111072 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1669997 usd
CY2023Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
11300 usd
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
124901 usd
CY2023Q3 skye Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
60274 usd
CY2022Q4 skye Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
15814 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
645830 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
657734 usd
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
22654 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
55451 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
921549 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1366994 usd
CY2023Q3 us-gaap Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
0 usd
CY2022Q4 us-gaap Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
95850 usd
CY2023Q3 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
6212319 usd
CY2022Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
6205310 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1848375 usd
CY2023Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
4144508 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
68677 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
78700 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13718562 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12119126 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
190510 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q3 us-gaap Liabilities
Liabilities
13909072 usd
CY2022Q4 us-gaap Liabilities
Liabilities
12119126 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12338910 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12338910 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3654116 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3654116 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
12338 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3654 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
101645539 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
63726057 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99962619 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66737765 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1695258 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3008054 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15604330 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9111072 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1254653 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1781724 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4227967 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4474531 usd
CY2023Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
21215214 usd
CY2022Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
21215214 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2235899 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1140558 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5357577 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4554131 usd
CY2023Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
151842 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
0 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2572338 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-556157 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24945834 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3127283 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33221254 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9584819 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3600 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5141 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24945834 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24945834 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-24945834 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3127283 usd
us-gaap Net Income Loss
NetIncomeLoss
-33224854 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
480466 usd
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
7009 usd
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-307086 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
1383285 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
skye Accrued Interest Conversion Expense
AccruedInterestConversionExpense
15952 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
21215214 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
45350 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-782265 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-121277 usd
skye Increase Decrease In Prepaid Expenses Due From Related Parties
IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties
0 usd
skye Increase Decrease In Prepaid Expenses Due From Related Parties
IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties
-13432 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
236779 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
86989 usd
skye Increase Decrease In Other Current Assets From Related Party
IncreaseDecreaseInOtherCurrentAssetsFromRelatedParty
0 usd
skye Increase Decrease In Other Current Assets From Related Party
IncreaseDecreaseInOtherCurrentAssetsFromRelatedParty
22542 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-112021 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
370136 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-113601 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
118086 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
60274 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
130823 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-11904 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
99533 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-60647 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-60489 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-570473 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1381 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-95850 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
102390 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10107460 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7872550 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
5532266 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 usd
skye Payment For Asset Acquisitions
PaymentForAssetAcquisitions
0 usd
skye Payment For Asset Acquisitions
PaymentForAssetAcquisitions
436554 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5533 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15556 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1076740 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6603473 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-452110 usd
CY2023Q3 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
265053 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
6026 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
236681 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
244922 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16465924 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-242955 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12961937 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8567615 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1249107 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8987578 usd
CY2023Q3 us-gaap Cash
Cash
5126245 usd
CY2022Q3 us-gaap Cash
Cash
415389 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
9084799 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4574 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14211044 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
419963 usd
us-gaap Interest Paid Net
InterestPaidNet
135917 usd
us-gaap Interest Paid Net
InterestPaidNet
4275 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3600 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
5141 usd
skye Common Stock Warrant Exercises
CommonStockWarrantExercises
282905 usd
skye Common Stock Warrant Exercises
CommonStockWarrantExercises
0 usd
skye Conversion Of Multi Draw Credit Agreement
ConversionOfMultiDrawCreditAgreement
1565470 usd
skye Conversion Of Multi Draw Credit Agreement
ConversionOfMultiDrawCreditAgreement
0 usd
skye Conversion Of Accrued Interest Due To Related Party
ConversionOfAccruedInterestDueToRelatedParty
31766 usd
skye Conversion Of Accrued Interest Due To Related Party
ConversionOfAccruedInterestDueToRelatedParty
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
951890 usd
skye Financing Of Insurance Premium
FinancingOfInsurancePremium
203884 usd
skye Financing Of Insurance Premium
FinancingOfInsurancePremium
275537 usd
skye Release Of Share Liability To Additional Paid In Capital
ReleaseOfShareLiabilityToAdditionalPaidInCapital
0 usd
skye Release Of Share Liability To Additional Paid In Capital
ReleaseOfShareLiabilityToAdditionalPaidInCapital
13000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
241134 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
skye Stock Issued For Assets Net Of Equity Issuance Costs
StockIssuedForAssetsNetOfEquityIssuanceCosts
20532846 usd
skye Stock Issued For Assets Net Of Equity Issuance Costs
StockIssuedForAssetsNetOfEquityIssuanceCosts
0 usd
skye Noncash Purchases Of Property And Equipment Incurred But Not Yet Paid
NoncashPurchasesOfPropertyAndEquipmentIncurredButNotYetPaid
0 usd
skye Noncash Purchases Of Property And Equipment Incurred But Not Yet Paid
NoncashPurchasesOfPropertyAndEquipmentIncurredButNotYetPaid
10455 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2980521 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5167520 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4780569 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102871 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
160207 usd
CY2023Q3 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
265053 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11734947 usd
CY2023Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
21609586 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
925550 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-24945834 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1695258 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5864166 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3043399 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2973092 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
144364 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3419278 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-301822 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
144124 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3127283 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-3284981 usd
CY2023Q3 skye Working Capital Earnings Deficit
WorkingCapitalEarningsDeficit
1567627 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99962619 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5126245 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24705766 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2922282 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-30648916 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9028662 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-24945834 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3127283 usd
us-gaap Net Income Loss
NetIncomeLoss
-33224854 usd
us-gaap Net Income Loss
NetIncomeLoss
-9589960 usd
CY2023Q1 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
6212319 usd
CY2023Q3 skye Loss Contingency Net Cash Received To Cover Legal Expenses
LossContingencyNetCashReceivedToCoverLegalExpenses
5000000 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
26349 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Unaudited Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Unaudited Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates and judgements as to the appropriate carrying values of equity instruments, debt with embedded features, estimates related to the Company's estimation of the percentage of completion under its research and development contracts, contingent legal liabilities, fair value of assets acquired, and the valuation of stock based compensation awards, which are not readily apparent from other sources.</span></div>
CY2023Q1 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
6212319 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
25842 usd
CY2022Q4 skye Legal Professional Fee Accrual
LegalProfessionalFeeAccrual
227350 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
127319 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0 usd
CY2023Q3 skye Travel And Entertainment Expenses Accrual
TravelAndEntertainmentExpensesAccrual
74500 usd
CY2022Q4 skye Travel And Entertainment Expenses Accrual
TravelAndEntertainmentExpensesAccrual
0 usd
CY2023Q3 skye Deposit From Divestment
DepositFromDivestment
0 usd
us-gaap Investment Tax Credit
InvestmentTaxCredit
170773 usd
CY2023Q3 us-gaap Investment Tax Credit
InvestmentTaxCredit
170773 usd
CY2023Q3 skye Asset Acquisition Share Price
AssetAcquisitionSharePrice
3.98
CY2023Q3 skye Tax Rebate Current
TaxRebateCurrent
526516 usd
CY2022Q4 skye Tax Rebate Current
TaxRebateCurrent
179687 usd
CY2023Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
324089 usd
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
204480 usd
CY2023Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
17314 usd
CY2022Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
97421 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
867919 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
481588 usd
CY2023Q3 skye Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
232588 usd
CY2022Q4 skye Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
40597 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
217994 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
134896 usd
CY2023Q3 skye Legal Professional Fee Accrual
LegalProfessionalFeeAccrual
162156 usd
CY2022Q4 skye Deposit From Divestment
DepositFromDivestment
553800 usd
CY2023Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
106992 usd
CY2022Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
410351 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
921549 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1366994 usd
CY2023Q3 skye Insurance Premium Expense
InsurancePremiumExpense
2162 usd
CY2022Q3 skye Insurance Premium Expense
InsurancePremiumExpense
1602 usd
skye Insurance Premium Expense
InsurancePremiumExpense
5764 usd
skye Insurance Premium Expense
InsurancePremiumExpense
4273 usd
CY2023Q3 skye Legal Fees Interest Expense
LegalFeesInterestExpense
-23320 usd
CY2022Q3 skye Legal Fees Interest Expense
LegalFeesInterestExpense
0 usd
CY2023Q3 skye Class Of Warrant Or Right Warrants Vested And Outstanding
ClassOfWarrantOrRightWarrantsVestedAndOutstanding
3280940 shares
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
59732 usd
skye Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-59406 usd
skye Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
0 usd
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
326 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
25.00
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
1383285 usd
CY2023Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
60274 usd
CY2022Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
44086 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
76227 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
130824 usd
skye Legal Fees Interest Expense
LegalFeesInterestExpense
158851 usd
skye Legal Fees Interest Expense
LegalFeesInterestExpense
0 usd
CY2023Q3 skye Bond Premium
BondPremium
59930 usd
CY2022Q3 skye Bond Premium
BondPremium
0 usd
skye Bond Premium
BondPremium
59930 usd
skye Bond Premium
BondPremium
0 usd
CY2023Q3 skye Premium On Irrevocable Letter Of Credit
PremiumOnIrrevocableLetterOfCredit
69861 usd
CY2022Q3 skye Premium On Irrevocable Letter Of Credit
PremiumOnIrrevocableLetterOfCredit
0 usd
skye Premium On Irrevocable Letter Of Credit
PremiumOnIrrevocableLetterOfCredit
69861 usd
skye Premium On Irrevocable Letter Of Credit
PremiumOnIrrevocableLetterOfCredit
0 usd
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
0 usd
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
0 usd
us-gaap Interest Expense Other
InterestExpenseOther
3102 usd
us-gaap Interest Expense Other
InterestExpenseOther
0 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
99587 usd
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
165082 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
99587 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
479133 usd
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2813 usd
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
459 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2813 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1333 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
271307 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
211229 usd
us-gaap Interest Expense
InterestExpense
476135 usd
us-gaap Interest Expense
InterestExpense
615563 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
160207 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
144124 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
394657 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
425846 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3573151 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4Y29D
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24945834 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24945834 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3127283 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3127283 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33224854 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33224854 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9589960 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9589960 usd
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7880546 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7880546 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1983700 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1983700 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5207411 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5207411 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1983566 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1983566 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.83
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2021Q3 skye Lessee Operating Lease Abatement Term
LesseeOperatingLeaseAbatementTerm
P2M
CY2021Q3 skye Lessee Operating Lease Initial Monthly Rent
LesseeOperatingLeaseInitialMonthlyRent
8067 usd
CY2021Q3 skye Lessee Operating Lease Annual Rent Increase Percent
LesseeOperatingLeaseAnnualRentIncreasePercent
0.03
CY2023Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P62M
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
26076 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
71910 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
22675 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
68026 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y29D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
25427 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
103216 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
106313 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
90797 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
325753 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
66566 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
259187 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
68677 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
190510 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
259187 usd
CY2023Q3 skye Legal Fees Interest Expense
LegalFeesInterestExpense
-23320 usd
CY2023Q3 skye Loss Contingency Net Cash Received To Cover Legal Expenses
LossContingencyNetCashReceivedToCoverLegalExpenses
5000000 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 skye Stock Repurchase Program Increase In Number Of Shares Outstanding Percent
StockRepurchaseProgramIncreaseInNumberOfSharesOutstandingPercent
0.05

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
skye-20230930_cal.xml Edgar Link unprocessable
0001516551-23-000100-index-headers.html Edgar Link pending
0001516551-23-000100-index.html Edgar Link pending
0001516551-23-000100.txt Edgar Link pending
0001516551-23-000100-xbrl.zip Edgar Link pending
exhibit105formoflockupagre.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skye-20230930.htm Edgar Link pending
skye-20230930.xsd Edgar Link pending
skye-20230930xex311.htm Edgar Link pending
skye-20230930xex312.htm Edgar Link pending
skye-20230930xex321.htm Edgar Link pending
skye-20230930xex322.htm Edgar Link pending
skye-20230930_def.xml Edgar Link unprocessable
skye-20230930_lab.xml Edgar Link unprocessable
skye-20230930_pre.xml Edgar Link unprocessable
skye-20230930_htm.xml Edgar Link completed